- Molecular NameArformoterol
- Synonym(R,R)-formoterol; arformoterol
- Weight344.411
- Drugbank_IDDB01274
- ACS_NO67346-49-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.32
- pkaN/A
- LogD (pH=7, predicted)-0.53
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.25
- LogSw (predicted, AB/LogsW2.0)12.75
- Sw (mg/ml) (predicted, ACD/Labs)0.54
- No.of HBond Donors4
- No.of HBond Acceptors6
- No.of Rotatable Bonds8
- TPSA90.82
- StatusFDA approved
- Administrationnebuliser
- PharmacologyA long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD).
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding58.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmArformoterol was almost entirely metabolized following oral administration of 35 mcg of radiolabeled arformoterol in eight healthy subjects. Direct conjugation of arformoterol with glucuronic acid was the major metabolic pathway. O-Desmethylation is a secondary route catalyzed by the CYP enzymes CYP2D6 and CYP2C19.
- Half life26 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityA death was reported in dogs after a single oral dose of 5 mg/kg (approximately 4500 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose.
- LD50 (rat)N/A
- LD50 (mouse)N/A